Published Date: 08 Mar 2023
3-year results show that patients who underwent low-risk aortic valve replacement continue to report lower rates of all-cause mortality and stroke with TAVI compared to surgery
Read Full NewsThe U.S. Department of Justice said on Thursday it would immediately loosen restrictions on some marijuana products and move quickly to reclassify the drug as less...
Pembrolizumab and nivolumab show favorable response rates with or without consolidation therapy.
Palbociclib slows cancer cell proliferation in patients with HR+/HER2- locally advanced or metastatic breast cancer.
1.
Cancer mortality continuing to decline, says report
2.
New study reveals racial disparities in breast cancer diagnosis and outcomes in Canada
3.
AI tool automates liver tumor detection and monitoring
4.
New Zealand and Australian breast cancer rates among the highest in the world, global study finds
5.
Preoperative MRI is useful for identifying additional disease in breast cancer patients with nodes positive.
1.
Interpreting Iron Studies: What Your Blood Results Really Mean
2.
Uncovering the Subtle Signs of Prostate Cancer: Early Detection is Key
3.
CAR-T Cell Therapy for B-Cell Acute Lymphoblastic Leukemia: A Comprehensive Review
4.
Unleashing the Oncolytic Arsenal: Talimogene Laherparepvec Monotherapy – A Targeted Cancer Immunotherapy Treatment
5.
Case Study: The Role of JAK Inhibitors in Myeloproliferative Disorders
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Newer Immunotherapies for Myeloma- A Comprehensive Overview
2.
Advances in Classification/ Risk Stratification of Plasma Cell Dyscrasias
3.
From Relapse to Remission : Chasing the Invisible and Redefining Long-Term Survival in Adult R/R B-Cell ALL
4.
An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- Panel Discussion- Part II
5.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part II
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation